INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56101, 'Carbamoylcholine (ophthalmic)', 'Promazine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56173/', '', 'Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56102, 'Carbamoylcholine (ophthalmic)', 'Promethazine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56174/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Trimethobenzamide, Astemizole, Desloratadine, Azelastine, Terfenadine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56103, 'Carbamoylcholine (ophthalmic)', 'Propantheline', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56175/', '', 'Papaverine, Alosetron, Isometheptene', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56104, 'Carbamoylcholine (ophthalmic)', 'Propiomazine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56176/', '', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56105, 'Carbamoylcholine (ophthalmic)', 'Protriptyline', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56177/', '', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56106, 'Carbamoylcholine (ophthalmic)', 'Mepyramine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56178/', '', 'Lidocaine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Trimethobenzamide, Astemizole, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56107, 'Carbamoylcholine (ophthalmic)', 'Quetiapine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56179/', '', 'Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56108, 'Carbamoylcholine (ophthalmic)', 'Quinidine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56180/', '', 'Amiodarone, Dronedarone, Tocainide, Lidocaine, Propafenone, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56109, 'Carbamoylcholine (ophthalmic)', 'Revefenacin', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56181/', '', 'Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56110, 'Carbamoylcholine (ophthalmic)', 'Risperidone', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56182/', '', 'Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56111, 'Carbamoylcholine (ophthalmic)', 'Rocuronium', 'Moderate', 'Carbachol antagonizes the action of nondepolarizing neuromuscular blocking agents due to antagonistic effects at the neuromuscular junction in skeletal muscle.', 'DDInter', 'The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56183/', '', 'Botulinum toxin type A', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56112, 'Carbamoylcholine (ophthalmic)', 'Scopolamine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56184/', '', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56113, 'Carbamoylcholine (ophthalmic)', 'Scopolamine (ophthalmic)', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56185/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56114, 'Carbamoylcholine (ophthalmic)', 'Solifenacin', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56186/', '', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56115, 'Carbamoylcholine (ophthalmic)', 'Succinylcholine', 'Moderate', 'Carbachol may prolong and enhance the action of depolarizing neuromuscular blocking agents due to synergistic effects at the neuromuscular junction in skeletal muscle. Patients may experience prolonged muscle weakness and apnea.', 'DDInter', 'Close observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56187/', '', 'Botulinum toxin type A', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56116, 'Carbamoylcholine (ophthalmic)', 'Thiethylperazine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56188/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Trimethobenzamide, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56117, 'Carbamoylcholine (ophthalmic)', 'Thioridazine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56189/', '', 'Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56118, 'Carbamoylcholine (ophthalmic)', 'Thiothixene', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56190/', '', 'Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56119, 'Carbamoylcholine (ophthalmic)', 'Tiotropium', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56191/', '', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56120, 'Carbamoylcholine (ophthalmic)', 'Tolterodine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56192/', '', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56121, 'Carbamoylcholine (ophthalmic)', 'Trifluoperazine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56193/', '', 'Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56122, 'Carbamoylcholine (ophthalmic)', 'Triflupromazine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56194/', '', 'Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56123, 'Carbamoylcholine (ophthalmic)', 'Trihexyphenidyl', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56195/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56124, 'Alimemazine', 'Carbamoylcholine (ophthalmic)', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56196/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Trimethobenzamide, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56125, 'Carbamoylcholine (ophthalmic)', 'Trimipramine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56197/', '', 'Citalopram, Sertraline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56126, 'Carbamoylcholine (ophthalmic)', 'Tripelennamine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56198/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Trimethobenzamide, Astemizole, Desloratadine, Azelastine, Terfenadine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56127, 'Carbamoylcholine (ophthalmic)', 'Triprolidine', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56199/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Dexchlorpheniramine, Loratadine, Trimethobenzamide, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56128, 'Carbamoylcholine (ophthalmic)', 'Tropicamide (ophthalmic)', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56200/', '', 'Tropicamide, Ephedrine, Ketorolac, Phenylephrine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56129, 'Carbamoylcholine (ophthalmic)', 'Trospium', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56201/', '', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56130, 'Carbamoylcholine (ophthalmic)', 'Tubocurarine', 'Moderate', 'Carbachol antagonizes the action of nondepolarizing neuromuscular blocking agents due to antagonistic effects at the neuromuscular junction in skeletal muscle.', 'DDInter', 'The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56202/', '', 'Botulinum toxin type A', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56131, 'Carbamoylcholine (ophthalmic)', 'Umeclidinium', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56203/', '', 'Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56132, 'Carbamoylcholine (ophthalmic)', 'Vecuronium', 'Moderate', 'Carbachol antagonizes the action of nondepolarizing neuromuscular blocking agents due to antagonistic effects at the neuromuscular junction in skeletal muscle.', 'DDInter', 'The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56204/', '', 'Botulinum toxin type A', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56133, 'Carbamoylcholine (ophthalmic)', 'Ziprasidone', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', 'DDInter', 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56205/', '', 'Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56134, 'Aminoglutethimide', 'Carbamazepine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of carbamazepine, which is primarily metabolized by the isoenzyme. The interaction has been reported with known CYP450 3A4 inducers such as phenobarbital, phenytoin, and primidone.', 'DDInter', 'Pharmacologic effects and serum concentrations of carbamazepine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the carbamazepine dosage adjusted as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56206/', '', 'Anastrozole, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56135, 'Aminophylline', 'Carbamazepine', 'Moderate', 'Carbamazepine may decrease theophylline serum levels. Also, theophyllines may decrease serum levels and effects of carbamazepine. The mechanisms may be related to induction of hepatic CYP450 metabolism.', 'DDInter', 'Close observation for clinical and laboratory evidence of altered effects is recommended for both agents. Patients should be advised to notify their physician if they experience loss of therapeutic effects.', 'Metabolism', 'Close observation for clinical and laboratory evidence of altered effects is recommended for both agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56207/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 'Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Bromotheophylline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56136, 'Amoxapine', 'Carbamazepine', 'Moderate', 'Carbamazepine may decrease serum concentrations of tricyclic antidepressants. The mechanism may be related to carbamazepine induction of CYP450 enzymes responsible for tricyclic antidepressant metabolism. Serum concentrations of carbamazepine may be increased by an unknown mechanism. Additionally, tricyclic antidepressants may counteract the anticonvulsant effects of carbamazepine by lowering the seizure threshold.', 'DDInter', 'Clinical monitoring of serum concentrations, patient response, seizure control, and tolerance is recommended whenever either agent is added to or discontinued from an existing regimen, or when the dosage is changed.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56208/', '', 'Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56137, 'Amprenavir', 'Carbamazepine', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56209/', '', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Levetiracetam, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More', 'Paritaprevir, Zanamivir, Velpatasvir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, Pibrentasvir, Rimantadine, Telbivudine, Entecavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56138, 'Anisindione', 'Carbamazepine', 'Moderate', 'Carbamazepine may induce the metabolism of warfarin and reduce its anticoagulant effect. The mechanism is induction of hepatic isoenzyme metabolism by carbamazepine. Carbamazepine may interact with other oral anticoagulants in a similar fashion.', 'DDInter', 'INR should be monitored whenever carbamazepine is started or discontinued in a patient receiving an oral anticoagulant. Patients should be advised to promptly report any signs of blood clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).', 'Metabolism', 'INR should be monitored whenever carbamazepine is started or discontinued in a patient receiving an oral anticoagulant.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56210/', '', 'Brivaracetam, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, Clonazepam, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56139, 'Carbamazepine', 'Artesunate', 'Moderate', 'Coadministration with potent inducers of uridine diphosphate glucuronosyltransferase (UGT) may decrease the peak plasma concentration (Cmax) and systemic exposure (AUC) of dihydroartemisinin (DHA), an active metabolite of artesunate and substrate of UGT 1A9 or 2B7. Reduced efficacy of artesunate may occur.', 'DDInter', 'The potential for diminished pharmacologic effects of artesunate should be considered during coadministration with potent UGT inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of artesunate should be considered during coadministration with potent UGT inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56211/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56140, 'Carbamazepine', 'Atracurium', 'Moderate', 'Carbamazepine may reduce the effects or duration of nondepolarizing neuromuscular blocking agents. The mechanism is unknown.', 'DDInter', 'Close observation for decreased neuromuscular blocking effect is recommended if a patient on carbamazepine must receive a nondepolarizing neuromuscular blocking agent.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56212/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56141, 'Carbamazepine', 'Azatadine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56213/', '', 'Tiagabine, Paramethadione, Phensuximide, Lamotrigine, Fosphenytoin, Phenacemide, Lacosamide', 'Chlorcyclizine, Astemizole, Azelastine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56142, 'Carbamazepine', 'Bedaquiline', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to the major N-monodesmethyl metabolite, M2. Because M2 is 4- to 6-fold less active than the parent drug in terms of antimycobacterial potency, the interaction may diminish the therapeutic effect of bedaquiline.', 'DDInter', 'The concomitant use of bedaquiline with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56214/', '', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Clonazepam, Paramethadione, Perampanel, Ganaxolone, More', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56143, 'Carbamazepine', 'Bendroflumethiazide', 'Moderate', 'Carbamazepine may cause clinically significant hyponatremia. Data show that the risk of hyponatremia may be additive when carbamazepine and hydrochlorothiazide are used concurrently. Carbamazepine and other diuretics may interact in a similar manner.', 'DDInter', 'Clinical monitoring of patient mental status and periodic measurement of serum sodium concentrations is recommended. Patients should be advised to notify their caregiver if they experience possible symptoms of hyponatremia such as nausea, vomiting, lethargy, weakness, muscle cramps, twitching, confusion, or seizures.', 'Synergism', 'Clinical monitoring of patient mental status and periodic measurement of serum sodium concentrations is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56215/', '', 'Tinidazole, Ascorbic acid, Oxytetracycline, Sulfamethoxazole, Ciclopirox, Sulfamethizole, Tioconazole, Diazoxide, Econazole, Sulfadiazine, Chloramphenicol, More', 'Brivaracetam, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56144, 'Carbamazepine', 'Benzthiazide', 'Moderate', 'Carbamazepine may cause clinically significant hyponatremia. Data show that the risk of hyponatremia may be additive when carbamazepine and hydrochlorothiazide are used concurrently. Carbamazepine and other diuretics may interact in a similar manner.', 'DDInter', 'Clinical monitoring of patient mental status and periodic measurement of serum sodium concentrations is recommended. Patients should be advised to notify their caregiver if they experience possible symptoms of hyponatremia such as nausea, vomiting, lethargy, weakness, muscle cramps, twitching, confusion, or seizures.', 'Synergism', 'Clinical monitoring of patient mental status and periodic measurement of serum sodium concentrations is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56216/', '', 'Tinidazole, Ascorbic acid, Oxytetracycline, Sulfamethoxazole, Ciclopirox, Sulfamethizole, Tioconazole, Diazoxide, Econazole, Sulfadiazine, Chloramphenicol, More', 'Brivaracetam, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56145, 'Carbamazepine', 'Bepridil', 'Major', 'Coadministration with carbamazepine may significantly decrease the plasma concentrations and pharmacologic effects of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nimodipine, nisoldipine). The proposed mechanism is carbamazepine induction of CYP450-mediated metabolism.', 'DDInter', 'Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers such as carbamazepine should generally be avoided. If coadministration is necessary, pharmacologic response should be monitored more closely following the initiation, discontinuation or change of dosage of carbamazepine, and the CCB dosage adjusted accordingly.', 'Metabolism', 'Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers such as carbamazepine should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56217/', '', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56146, 'Carbamazepine', 'Berotralstat', 'Major', 'Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations and pharmacologic effects of berotralstat, a substrate of this efflux transporter.', 'DDInter', 'Due to the potential for diminished pharmacologic effects of berotralstat, its concomitant use with P-gp inducers, including but not limited to rifampin and St. John''s wort, should be avoided. Alternative therapeutic agents with less P-gp induction potential should be considered whenever possible.', 'Excretion', 'Due to the potential for diminished pharmacologic effects of berotralstat, its concomitant use with P-gp inducers, including but not limited to rifampin and St.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56218/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56147, 'Carbamazepine', 'Boceprevir', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of boceprevir, which is partially metabolized by the isoenzyme.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of boceprevir with potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56219/', '', 'Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Ezogabine, Paramethadione, Mephenytoin, Methsuximide, Fenfluramine, Lamotrigine, More', 'Paritaprevir, Zanamivir, Velpatasvir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, Pibrentasvir, Rimantadine, Telbivudine, Entecavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56148, 'Carbamazepine', 'Butabarbital', 'Minor', 'Coadministration with a barbiturate may decrease the plasma concentrations of carbamazepine and increase concentrations of its active 10,11-epoxide metabolite. The mechanism is barbiturate induction of CYP450 3A4, the isoenzyme responsible for the metabolism of carbamazepine to carbamazepine-10,11-epoxide (CBZ-E). Until more data are available, it may be reasonable to monitor serum carbamazepine levels more closely whenever a barbiturate (if used for more than a few days) is added to or withdrawn from therapy.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56220/', '', 'Lacosamide, Methylphenobarbital', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56149, 'Carbamazepine', 'Butalbital', 'Minor', 'Coadministration with a barbiturate may decrease the plasma concentrations of carbamazepine and increase concentrations of its active 10,11-epoxide metabolite. The mechanism is barbiturate induction of CYP450 3A4, the isoenzyme responsible for the metabolism of carbamazepine to carbamazepine-10,11-epoxide (CBZ-E). Until more data are available, it may be reasonable to monitor serum carbamazepine levels more closely whenever a barbiturate (if used for more than a few days) is added to or withdrawn from therapy.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56221/', '', 'Lacosamide, Methylphenobarbital', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56150, 'Carbamazepine', 'Pentoxyverine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56222/', '', 'Lacosamide', 'Benzonatate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56151, 'Carbamazepine', 'Carbinoxamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56223/', '', 'Lacosamide', 'Chlorcyclizine, Astemizole, Azelastine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56152, 'Carbamazepine', 'Cariprazine', 'Moderate', 'Coadministration with potent or moderate inducers of CYP450 3A4 is expected to alter the pharmacokinetics of cariprazine and its major active metabolites. Cariprazine is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2D6 to desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR). DCAR is further metabolized to DDCAR by CYP450 3A4 and 2D6, and DDCAR is then metabolized by CYP450 3A4 to a hydroxylated metabolite. Both DCAR and DDCAR have in vitro receptor binding profiles similar to the parent drug and are considered pharmacologically equipotent to cariprazine.', 'DDInter', 'Concomitant use of cariprazine with potent or moderate CYP450 3A4 inducers has not been evaluated and is not recommended.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56224/', '', 'Lacosamide', 'Amisulpride', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56153, 'Carbamazepine', 'Carisoprodol', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56225/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56154, 'Carbamazepine', 'Caspofungin', 'Major', 'Coadministration with inducers or mixed inducer/inhibitors of certain metabolic pathways may produce clinically meaningful reductions in the plasma concentrations of caspofungin. This assumption is based on results from regression analyses of patient pharmacokinetic data derived from a small number of patients who were administered the drugs efavirenz, nelfinavir, nevirapine, phenytoin, rifampin, dexamethasone, or carbamazepine prior to and/or concurrently with caspofungin. There are no data from formal drug interaction studies to evaluate these regression analyses, and it is not known which metabolic pathway involved in caspofungin clearance may be inducible.', 'DDInter', 'The manufacturer of caspofungin states that during coadministration with efavirenz, nelfinavir, nevirapine, phenytoin, rifampin, dexamethasone or carbamazepine, an increase in the daily dosage to 70 mg (following the usual 70 mg loading dose) should be considered in patients who are not clinically responding.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56226/', '', 'Flucytosine, Anidulafungin, Micafungin, Oteseconazole', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56155, 'Carbamazepine', 'Cefixime', 'Minor', 'The concomitant administration of cefixime may increase carbamazepine serum concentrations. The mechanism and clinical significance are unknown. Until more information is available, monitoring of carbamazepine levels may be helpful in detecting a possible interaction. Patients should be advised to report possible symptoms of carbamazepine toxicity (nausea, visual disturbances, dizziness, or ataxia).', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56227/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', 'Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefalotin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56156, 'Cenobamate', 'Carbamazepine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of carbamazepine. The proposed mechanism is cenobamate-mediated induction of CYP450 3A4, an isoenzyme involved in the hepatic metabolism of carbamazepine.', 'DDInter', 'The potential for diminished therapeutic response to carbamazepine should be considered during coadministration with cenobamate. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the carbamazepine dosage adjusted as necessary.', 'Metabolism', 'The potential for diminished therapeutic response to carbamazepine should be considered during coadministration with cenobamate.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56228/', '', 'Lacosamide, Cenobamate', 'Lacosamide, Carbamazepine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56157, 'Ceritinib', 'Carbamazepine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme.', 'DDInter', 'Concomitant use of ceritinib with potent CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56229/', '', 'Ethotoin, Brivaracetam, Gabapentin, Topiramate, Paramethadione, Mephenytoin, Perampanel, Methsuximide, Fenfluramine, Lamotrigine, Phensuximide, More', 'Alectinib, Lenvatinib, Trametinib, Dacomitinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56158, 'Certolizumab pegol', 'Carbamazepine', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56230/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Inebilizumab, Belimumab, Sutimlimab, Risankizumab, Antilymphocyte immunoglobulin (horse), More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56159, 'Cevimeline', 'Carbamazepine', 'Minor', 'Coadministration with inducers of CYP450 3A4 may theoretically decrease the plasma concentrations of cevimeline, which is a substrate of the isoenzyme. However, the clinical relevance has not been established, since cevimeline is also metabolized by CYP450 2D6, which is not inducible to any significant extent.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56231/', '', 'Ambenonium, Bethanechol, Neostigmine', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Rufinamide, Clonazepam, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56160, 'Carbamazepine', 'Activated charcoal', 'Moderate', 'Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects or of the toxicity of many drugs. Activated charcoal may adsorb any therapeutic agents administered while it is in the gastrointestinal tract.', 'DDInter', 'The regular ingestion of charcoal should be avoided by patients requiring maintenance medications. If concomitant use is necessary, the dosage or route of administration may need to be altered.', 'Absorption', 'The regular ingestion of charcoal should be avoided by patients requiring maintenance medications.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56232/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Rufinamide, Clonazepam, More', 'Pectin, Kaolin, Attapulgite', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56161, 'Clofedanol', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56233/', '', 'Lacosamide', 'Benzonatate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56162, 'Chloral hydrate', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56234/', '', 'Lacosamide, Paramethadione, Phensuximide, Phenacemide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56163, 'Chlordiazepoxide', 'Carbamazepine', 'Moderate', 'Some antiepileptic agents such as carbamazepine and phenytoin significantly reduce the effect of oral midazolam. The mechanism may be due to enhanced gut and liver metabolism of midazolam (via CYP450 3A4 enzyme induction by carbamazepine). Parenteral midazolam is not likely to be affected. Other oral benzodiazepines metabolized by the 3A4 isoenzyme may interact similarly.', 'DDInter', 'Patients receiving this combination should be monitored for clinical response. Alternative oral sedative hypnotics may be preferable in patients receiving carbamazepine.', 'Metabolism', 'Patients receiving this combination should be monitored for clinical response.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56235/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56164, 'Chlormezanone', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56236/', '', 'Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56165, 'Chloroquine', 'Carbamazepine', 'Moderate', 'Coadministration with strong inducers of CYP450 2C8 or CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of hydroxychloroquine. When rifampin, a CYP450 2C8 and CYP450 3A4 strong inducer, was administered concomitantly with hydroxychloroquine, a lack of efficacy of hydroxychloroquine was reported. Because hydroxychloroquine and chloroquine and have similar structures and metabolic elimination pathways, a similar interaction could be observed for chloroquine.Chloroquine or hydroxychloroquine may lower the convulsive threshold, which may antagonize the action of antiepileptic medications. Seizures have been rarely reported in patients on chloroquine or hydroxychloroquine therapy. The mechanism is unknown.', 'DDInter', 'Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a strong CYP450 3A4 or 2C8 inducer. Clinical and laboratory monitoring should be considered whenever a strong CYP450 3A4 or 2C8 inducer is added to or withdrawn from therapy with hydroxychloroquine or chloroquine, and the dosage adjusted as necessary. The potential risks and benefits should be evaluated prior to initiating chloroquine or hydroxychloroquine in patients on anticonvulsant therapy. In addition, patients with a history of epilepsy should be advised about the risk of chloroquine/hydroxychloroquine-induced seizures. Alternative anti-malarial agents may be required. Local treatment guidelines should be consulted.', 'Metabolism, Antagonism', 'Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a strong CYP450 3A4 or 2C8 inducer.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56237/', '', 'Clonazepam, Cannabidiol, Cenobamate, Fenfluramine, Ganaxolone', 'Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56166, 'Chlorothiazide', 'Carbamazepine', 'Moderate', 'Carbamazepine may cause clinically significant hyponatremia. Data show that the risk of hyponatremia may be additive when carbamazepine and hydrochlorothiazide are used concurrently. Carbamazepine and other diuretics may interact in a similar manner.', 'DDInter', 'Clinical monitoring of patient mental status and periodic measurement of serum sodium concentrations is recommended. Patients should be advised to notify their caregiver if they experience possible symptoms of hyponatremia such as nausea, vomiting, lethargy, weakness, muscle cramps, twitching, confusion, or seizures.', 'Synergism', 'Clinical monitoring of patient mental status and periodic measurement of serum sodium concentrations is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56238/', '', 'Brivaracetam, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Tinidazole, Ascorbic acid, Oxytetracycline, Sulfamethoxazole, Ciclopirox, Sulfamethizole, Tioconazole, Diazoxide, Econazole, Sulfadiazine, Chloramphenicol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56167, 'Chlorphenesin', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56239/', '', 'Lacosamide, Paramethadione, Phensuximide, Phenacemide', 'Salicylic acid, Selenium Sulfide, Thiabendazole, Ciclopirox, Econazole, Flucytosine, Tioconazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56168, 'Chlorpromazine', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56240/', '', 'Amisulpride', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56169, 'Chlorzoxazone', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56241/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56170, 'Cimetidine', 'Carbamazepine', 'Moderate', 'Cimetidine may increase carbamazepine levels by inhibiting its CYP450 3A4 hepatic metabolism. Carbamazepine toxicity is possible.', 'DDInter', 'If these drugs must be used together, close observation for clinical and laboratory evidence of carbamazepine toxicity is recommended. Patients should be advised to report possible symptoms of carbamazepine toxicity (nausea, visual disturbances, dizziness, or ataxia). Dose reductions may be required. Famotidine, nizatidine and ranitidine are not expected to inhibit hepatic metabolism and may be considered as alternatives.', 'Metabolism', 'If these drugs must be used together, close observation for clinical and laboratory evidence of carbamazepine toxicity is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56242/', '', 'Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Levofloxacin', 'Brivaracetam, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56171, 'Cisatracurium', 'Carbamazepine', 'Moderate', 'Carbamazepine may reduce the effects or duration of nondepolarizing neuromuscular blocking agents. The mechanism is unknown.', 'DDInter', 'Close observation for decreased neuromuscular blocking effect is recommended if a patient on carbamazepine must receive a nondepolarizing neuromuscular blocking agent.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56243/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56172, 'Cisplatin', 'Carbamazepine', 'Moderate', 'Limited data suggest that coadministration with cisplatin and/or doxorubicin may decrease the plasma concentrations and pharmacologic effects of carbamazepine. The exact mechanism of interaction is unknown.', 'DDInter', 'Serum carbamazepine levels should be monitored more closely during therapy with cisplatin and/or doxorubicin. Dosage adjustments may be required.', 'Others', 'Serum carbamazepine levels should be monitored more closely during therapy with cisplatin and/or doxorubicin.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56244/', '', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Mitotane, Aflibercept, Trastuzumab, Talimogene laherparepvec, Estramustine, More', 'Brivaracetam, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Rufinamide, Paramethadione, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56173, 'Citalopram', 'Carbamazepine', 'Minor', 'The manufacturer of citalopram has reported that concomitant administration of carbamazepine with citalopram or escitalopram (both CYP450 3A4 substrates), did not significantly affect carbamazepine pharmacokinetics or citalopram or escitalopram levels. However, due to the enzyme inducing property of carbamazepine, the potential for increased clearance of citalopram should be considered. Dosage adjustments may be necessary if an interaction is suspected.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56245/', '', 'Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56174, 'Cladribine', 'Carbamazepine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', 'DDInter', 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56246/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Inebilizumab, Belimumab, Sutimlimab, Risankizumab, Antilymphocyte immunoglobulin (horse), More', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56175, 'Clarithromycin', 'Carbamazepine', 'Major', 'Some macrolide antibiotics can significantly increase serum carbamazepine levels. The mechanism is probably inhibition of hepatic CYP450 3A4 isoenzymes. Severe carbamazepine toxicity has been reported. At the same time, carbamazepine may induce the CYP450 3A4 metabolism of macrolides. This may lead to sub-therapeutic levels of macrolides and a decreased antibiotic effect.', 'DDInter', 'Monitoring of carbamazepine blood levels is recommended, and the patient should be carefully observed for signs of carbamazepine toxicity. Patients should be advised to report signs of carbamazepine toxicity (nausea, visual disturbances, dizziness, or ataxia) to their physicians. The carbamazepine dosage may require reduction. Monitor for a reduction in the antimicrobial effects of the macrolide if this combination must be used. Alternative antimicrobial therapy, if available, is generally recommended for patients on carbamazepine.', 'Metabolism', 'Monitoring of carbamazepine blood levels is recommended, and the patient should be carefully observed for signs of carbamazepine toxicity.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56247/', '', 'Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More', 'Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Levofloxacin, Lincomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56176, 'Clemastine', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56248/', '', 'Tetracaine, Chlorcyclizine, Astemizole, Azelastine', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56177, 'Clindamycin', 'Carbamazepine', 'Moderate', 'Coadministration with strong CYP450 3A4 inducers may decrease plasma concentrations and antimicrobial effects of clindamycin, which is metabolized predominantly by the isoenzyme.', 'DDInter', 'Monitor closely for diminished therapeutic response to clindamycin during coadministration with strong CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy with clindamycin. An alternative agent with no or minimal CYP450 3A4-inducing activity may also be considered.', 'Metabolism', 'Monitor closely for diminished therapeutic response to clindamycin during coadministration with strong CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56249/', '', 'Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More', 'Vitamin A, Chloramphenicol, Fluorometholone, Dapsone, Azelaic acid, Adapalene, Lincomycin, Dirithromycin, Tinidazole, Ascorbic acid, Oxytetracycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56178, 'Clobazam', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56250/', '', 'Oxcarbazepine, Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56179, 'Clofarabine', 'Carbamazepine', 'Moderate', 'The liver is a known target organ for clofarabine toxicity, and concomitant use of other potentially hepatotoxic agents may increase the risk of liver injury. Severe and fatal hepatotoxicity has occurred with the use of clofarabine alone.', 'DDInter', 'Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56251/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Pemetrexed, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56180, 'Clomipramine', 'Carbamazepine', 'Moderate', 'Carbamazepine may decrease serum concentrations of tricyclic antidepressants. The mechanism may be related to carbamazepine induction of CYP450 enzymes responsible for tricyclic antidepressant metabolism. Serum concentrations of carbamazepine may be increased by an unknown mechanism. Additionally, tricyclic antidepressants may counteract the anticonvulsant effects of carbamazepine by lowering the seizure threshold.', 'DDInter', 'Clinical monitoring of serum concentrations, patient response, seizure control, and tolerance is recommended whenever either agent is added to or discontinued from an existing regimen, or when the dosage is changed.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56252/', '', 'Lacosamide', 'Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56181, 'Clonazepam', 'Carbamazepine', 'Moderate', 'Carbamazepine may reduce serum clonazepam levels. The mechanism may be related to induction of metabolism. The risk of CNS-depressant side effects, such as sedation and apathy, may be increased with this combination.', 'DDInter', 'If these drugs must be used together, observation for clinical and laboratory evidence of altered clonazepam effect is recommended.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56253/', '', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 'Lacosamide, Carbamazepine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56182, 'Clonidine', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56254/', '', 'Lacosamide', 'Neostigmine, Acetylcholine, Betaxolol, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Brimonidine, Guanethidine, Levobunolol, Rauwolfia serpentina root, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56183, 'Clorazepic acid', 'Carbamazepine', 'Moderate', 'Some antiepileptic agents such as carbamazepine and phenytoin significantly reduce the effect of oral midazolam. The mechanism may be due to enhanced gut and liver metabolism of midazolam (via CYP450 3A4 enzyme induction by carbamazepine). Parenteral midazolam is not likely to be affected. Other oral benzodiazepines metabolized by the 3A4 isoenzyme may interact similarly.', 'DDInter', 'Patients receiving this combination should be monitored for clinical response. Alternative oral sedative hypnotics may be preferable in patients receiving carbamazepine.', 'Metabolism', 'Patients receiving this combination should be monitored for clinical response.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56255/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56184, 'Clozapine', 'Carbamazepine', 'Major', 'The use of clozapine with other potentially myelotoxic agents such as carbamazepine may increase the risk and/or severity of hematologic toxicity. Clozapine alone is associated with a significant risk of agranulocytosis, defined as an absolute neutrophil count (ANC) of less than 500/mm3. Case reports also suggest that carbamazepine may decrease the pharmacologic effects of clozapine. The mechanism may involve induction of CYP450 hepatic metabolism by carbamazepine. Increased serum clozapine levels have been reported after discontinuation of carbamazepine therapy.', 'DDInter', 'The use of clozapine in combination with other agents having a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function is considered contraindicated.', 'Metabolism, Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56256/', '', 'Amisulpride', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56185, 'Cobimetinib', 'Carbamazepine', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of cobimetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56257/', '', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More', 'Alectinib, Lenvatinib, Trametinib, Dacomitinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56186, 'Codeine', 'Carbamazepine', 'Moderate', 'Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels. This interaction may lead to reduced codeine efficacy and potentially initiate the onset of withdrawal symptoms in patients who are physically dependent. In addition, patients may be at an increased risk of CNS and/or respiratory-depressant effects from increased levels of codeine once concomitant therapy with the CYP450 3A4 inducer is ceased.', 'DDInter', 'The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended. Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Metabolism', 'The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56258/', '', 'Naloxone, Benzonatate', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56187, 'Colesevelam', 'Carbamazepine', 'Moderate', 'INTERVAL: Colesevelam may decrease the gastrointestinal absorption of coadministered drugs. Approximately 20% to 40% reductions in systemic exposure (AUC) and 10% to 45% reductions in peak plasma concentration (Cmax) have been reported for cyclosporine, ethinyl estradiol, glimepiride, glyburide, levothyroxine, olmesartan, and sustained-release verapamil during coadministration with colesevelam.', 'DDInter', 'In general, drugs with a narrow therapeutic index as well as those that have been shown to interact with colesevelam should be administered at least 4 hours before the colesevelam dose. Clinical and laboratory monitoring of drug levels and effects should be considered.', 'Absorption', 'In general, drugs with a narrow therapeutic index as well as those that have been shown to interact with colesevelam should be administered at least 4 hours before the colesevelam dose.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56259/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Ethotoin, Rufinamide, Clonazepam, More', 'Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Colestipol, Bempedoic acid, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56188, 'Conivaptan', 'Carbamazepine', 'Moderate', 'Coadministration with conivaptan may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by conivaptan.', 'DDInter', 'Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever conivaptan is added to or withdrawn from therapy, or the combination avoided altogether.', 'Metabolism', 'Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56260/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56189, 'Copanlisib', 'Carbamazepine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', 'Concomitant use of copanlisib with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56261/', '', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More', 'Alectinib, Lenvatinib, Trametinib, Dacomitinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56190, 'Corticotropin', 'Carbamazepine', 'Moderate', 'Carbamazepine may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by carbamazepine.', 'DDInter', 'Patients treated concomitantly with carbamazepine may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever carbamazepine is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Patients treated concomitantly with carbamazepine may require higher dosages of corticosteroids or adrenocorticotropic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56262/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56191, 'Carbamazepine', 'Tetracosactide', 'Moderate', 'Carbamazepine may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by carbamazepine.', 'DDInter', 'Patients treated concomitantly with carbamazepine may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever carbamazepine is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Patients treated concomitantly with carbamazepine may require higher dosages of corticosteroids or adrenocorticotropic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56263/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56192, 'Crizotinib', 'Carbamazepine', 'Major', 'Coadministration with strong CYP450 3A4 inducers may decrease plasma concentrations and pharmacologic effects of crizotinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of crizotinib with strong CYP450 3A4 inducers such as rifampin, carbamazepine, phenobarbital, and phenytoin should generally be avoided. Some authorities also advise against concomitant use with moderate CYP450 3A4 inducers.', 'Metabolism', 'Concomitant use of crizotinib with strong CYP450 3A4 inducers such as rifampin, carbamazepine, phenobarbital, and phenytoin should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56264/', '', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, More', 'Alectinib, Lenvatinib, Trametinib, Dacomitinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56193, 'Cyclizine', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56265/', '', 'Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide', 'Chlorcyclizine, Astemizole, Azelastine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56194, 'Cyclobenzaprine', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56266/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56195, 'Cyclophosphamide', 'Carbamazepine', 'Moderate', 'Coadministration with carbamazepine may result in decreased plasma concentrations of cyclophosphamide and thiotepa, while concentrations of their main active metabolites increase. The proposed mechanism is carbamazepine induction of CYP450 2B6 and 3A4, the isoenzymes responsible for the bioactivation of cyclophosphamide and thiotepa to 4-hydroxycyclophosphamide and tepa, respectively.', 'DDInter', 'Given the potential for interaction and the high degree of interpatient variability with respect to hepatic enzyme activities, the use of cyclophosphamide or thiotepa in combination with carbamazepine should be avoided if possible. Anticonvulsants with no significant effects on CYP450 hepatic enzymes such as valproic acid, lamotrigine, or gabapentin may be appropriate alternatives. If carbamazepine is required, consideration should be given to dosage reduction of the chemotherapeutic agents. In addition, plasma levels of the active metabolites should be monitored to guide further dosing.', 'Metabolism', 'Given the potential for interaction and the high degree of interpatient variability with respect to hepatic enzyme activities, the use of cyclophosphamide or thiotepa in combination with carbamazepine should be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56267/', '', 'Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Melphalan, Melphalan flufenamide, Uracil mustard', 'Brivaracetam, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56196, 'Cyclosporine', 'Carbamazepine', 'Major', 'Carbamazepine may decrease cyclosporine serum concentrations to subtherapeutic levels due to induction of hepatic metabolism of cyclosporine.', 'DDInter', 'This combination should be avoided in patients where maintenance of therapeutic cyclosporine levels is critical. Cyclosporine serum concentrations should be monitored when carbamazepine is added to or discontinued from the patient''s regimen, or when the carbamazepine dosage is changed. Patients should be carefully monitored for lack of therapeutic effect. The dosage of cyclosporine may need to be increased.', 'Metabolism', 'This combination should be avoided in patients where maintenance of therapeutic cyclosporine levels is critical.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56268/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Inebilizumab, Belimumab, Sutimlimab, Risankizumab, Antilymphocyte immunoglobulin (horse), More', 'Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56197, 'Cyproheptadine', 'Carbamazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56269/', '', 'Chlorcyclizine, Astemizole, Azelastine', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56198, 'Dabrafenib', 'Carbamazepine', 'Moderate', 'Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.', 'DDInter', 'Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.', 'Metabolism', 'Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56270/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Alectinib, Lenvatinib, Trametinib, Dacomitinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56199, 'Daclatasvir', 'Carbamazepine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56271/', '', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', 'Paritaprevir, Zanamivir, Velpatasvir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, Pibrentasvir, Rimantadine, Telbivudine, Entecavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56200, 'Danazol', 'Carbamazepine', 'Moderate', 'Danazol may increase carbamazepine levels by inhibiting the CYP450 3A4 hepatic metabolism of carbamazepine. Carbamazepine toxicity is possible.', 'DDInter', 'If these drugs must be used together, close observation for clinical and laboratory evidence of carbamazepine toxicity is recommended. Patients should be advised to report possible signs of carbamazepine toxicity (nausea, visual disturbances, dizziness, or ataxia). Dose adjustments may be required.', 'Metabolism', 'If these drugs must be used together, close observation for clinical and laboratory evidence of carbamazepine toxicity is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56272/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', 'Prasterone', 1767369485);
